Caprelsa FDA Approval History
FDA Approved: Yes (First approved April 6, 2011)
Brand name: Caprelsa
Generic name: vandetanib
Dosage form: Tablets
Treatment for: Thyroid Cancer
Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.
Development Timeline for Caprelsa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.